{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:14:28Z","timestamp":1787732068522,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Nursing Clinical Research Climbing Program Project of the First Affiliated Hospital of Guangxi Medical University","award":["YYZS2022011"],"award-info":[{"award-number":["YYZS2022011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both insulin resistance and low-grade inflammation contribute to liver disease development, yet their combined predictive role remains unclear at the population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective nationwide cohort study, we analyzed 9,302 participants aged\u2009\u2265\u200945 years from the China Health and Retirement Longitudinal Study who were free of liver disease at baseline. Additionally, CTI was calculated as 0.412 \u00d7 ln (C-reactive protein [CRP, mg\/L])\u2009+\u2009ln((triglycerides [TG, mg\/dL] \u00d7 fasting plasma glucose [FPG, mg\/dL])\/2). Incident self-reported, physician-diagnosed liver disease was identified during follow-up interviews. Associations between CTI and liver disease were assessed using Cox regression, Kaplan\u2013Meier survival curves, and restricted cubic splines analyses. Subgroup and mediation analyses were conducted for low-density and high-density lipoprotein cholesterol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 81,229 person-years of follow-up, higher CTI was independently associated with an increased risk of incident self-reported, physician-diagnosed liver disease, with risk increasing progressively across CTI quartiles. This positive association was consistent in men and women, with approximately linear dose\u2013response relationships in both sexes and no meaningful sex differences. Mediation through low- and high-density lipoprotein cholesterol was negligible. Findings remain robust in multiple sensitivity analyses, including exclusion of participants who reported high-risk alcohol consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated CTI is a simple, low-cost biomarker that may help identify individuals at increased risk of liver disease, particularly in settings where comprehensive liver function panels are unavailable. Rather than replacing guideline-recommended fibrosis scores, CTI may serve as a complementary early risk indicator to support population-level risk stratification and inform targeted prevention and follow-up efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04588-2","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:08:59Z","timestamp":1767492539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of the C-reactive protein\u2013triglyceride\u2013glucose index with liver disease risk: findings from a nationwide Chinese cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Jinpeng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingran","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"4588_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cgh.2021.10.036","volume":"21","author":"C Griffin","year":"2023","unstructured":"Griffin C, Agbim U, Ramani A, Shankar N, Kanwal F, Asrani SK. Underestimation of Cirrhosis-Related mortality in the medicare eligible Population, 1999\u20132018. Clin Gastroenterol Hepatol. 2023;21:223\u2013e2253. https:\/\/doi.org\/10.1016\/j.cgh.2021.10.036.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4588_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J Hepatol"},{"key":"4588_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","volume":"71","author":"J Xiao","year":"2019","unstructured":"Xiao J, Wang F, Wong N-K, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, He W, You H, Miao Y, Liu X, Meng M, Gao B, Wang H, Li C. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71:212\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.004.","journal-title":"J Hepatol"},{"key":"4588_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","volume":"165","author":"S Man","year":"2023","unstructured":"Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C, Lv J, Liu H, Wang B, Li L. Prevalence of liver steatosis and fibrosis in the general population and various High-Risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165:1025\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2023.05.053.","journal-title":"Gastroenterology"},{"key":"4588_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"4588_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"4588_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/apt.17308","volume":"57","author":"A Henry","year":"2023","unstructured":"Henry A, Paik JM, Austin P, Eberly KE, Golabi P, Younossi I, Henry L, Gerber L, Younossi ZM. Vigorous physical activity provides protection against All-cause deaths among adults patients with nonalcoholic fatty liver disease (<\u2009span Style=font-Variant:Small-Caps;>NAFLD). Aliment Pharmacol Ther. 2023;57:709\u201322. https:\/\/doi.org\/10.1111\/apt.17308.","journal-title":"Aliment Pharmacol Ther"},{"key":"4588_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg F, Byrne CD, Pirola CJ, M\u00e4nnist\u00f6 V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191\u2013206. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.030.","journal-title":"J Hepatol"},{"key":"4588_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"Simental-Mend\u00eda LE, Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299\u2013304. https:\/\/doi.org\/10.1089\/met.2008.0034.","journal-title":"Metab Syndr Relat Disord"},{"key":"4588_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2024.08.026","volume":"131","author":"Y Sun","year":"2025","unstructured":"Sun Y, Ji H, Sun W, An X, Lian F. Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseases. Eur J Intern Med. 2025;131:3\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2024.08.026.","journal-title":"Eur J Intern Med"},{"key":"4588_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12933-024-02392-y","volume":"23","author":"SS Nayak","year":"2024","unstructured":"Nayak SS, Kuriyakose D, Polisetty LD, Patil AA, Ameen D, Bonu R, Shetty SP, Biswas P, Ulrich MT, Letafatkar N, Habibi A, Keivanlou M-H, Nobakht S, Alotaibi A, Hassanipour S, Amini-Salehi E. Diagnostic and prognostic value of triglyceride glucose index: A comprehensive evaluation of Meta-Analysis. Cardiovasc Diabetol. 2024;23:310. https:\/\/doi.org\/10.1186\/s12933-024-02392-y.","journal-title":"Cardiovasc Diabetol"},{"key":"4588_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","volume":"23","author":"Q Chen","year":"2024","unstructured":"Chen Q, Hu P, Hou X, Sun Y, Jiao M, Peng L, Dai Z, Yin X, Liu R, Li Y, Zhu C. Association between Triglyceride-Glucose related indices and mortality among individuals with Non-Alcoholic fatty liver disease or metabolic Dysfunction-Associated steatotic liver disease. Cardiovasc Diabetol. 2024;23:232. https:\/\/doi.org\/10.1186\/s12933-024-02343-7.","journal-title":"Cardiovasc Diabetol"},{"key":"4588_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-007-2060-x","volume":"42","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-Sensitivity C-Reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573\u201382. https:\/\/doi.org\/10.1007\/s00535-007-2060-x.","journal-title":"J Gastroenterol"},{"key":"4588_CR14","doi-asserted-by":"publisher","first-page":"905266","DOI":"10.3389\/fendo.2022.905266","volume":"13","author":"G-T Ruan","year":"2022","unstructured":"Ruan G-T, Xie H-L, Zhang H-Y, Liu C-A, Ge Y-Z, Zhang Q, Wang Z-W, Zhang X, Tang M, Song M-M, Zhang X-W, Yang M, Chen Y-B, Yu K-Y, Deng L, Gong Y-Z, Hu W, Wang K-H, Cong M-H, et al. A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer. Front Endocrinol (Lausanne). 2022;13:905266. https:\/\/doi.org\/10.3389\/fendo.2022.905266.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4588_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-024-02244-9","volume":"23","author":"C Cui","year":"2024","unstructured":"Cui C, Liu L, Qi Y, Han N, Xu H, Wang Z, Shang X, Han T, Zha Y, Wei X, Wu Z. Joint association of TyG index and high sensitivity C-Reactive protein with cardiovascular disease: A National cohort study. Cardiovasc Diabetol. 2024;23:156. https:\/\/doi.org\/10.1186\/s12933-024-02244-9.","journal-title":"Cardiovasc Diabetol"},{"key":"4588_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-025-02686-9","volume":"24","author":"G Huo","year":"2025","unstructured":"Huo G, Tang Y, Liu Z, Cao J, Yao Z, Zhou D. Association between C-Reactive Protein-Triglyceride glucose index and stroke risk in different glycemic status: insights from the China health and retirement longitudinal study (CHARLS). Cardiovasc Diabetol. 2025;24:142. https:\/\/doi.org\/10.1186\/s12933-025-02686-9.","journal-title":"Cardiovasc Diabetol"},{"key":"4588_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40170-024-00332-8","volume":"12","author":"G-T Ruan","year":"2024","unstructured":"Ruan G-T, Deng L, Xie H-L, Shi J-Y, Liu X-Y, Zheng X, Chen Y, Lin S-Q, Zhang H-Y, Liu C-A, Ge Y-Z, Song M-M, Hu C-L, Zhang X-W, Yang M, Hu W, Cong M-H, Zhu L-C, Wang K-H, et al. Systemic inflammation and insulin Resistance-Related indicator predicts poor outcome in patients with cancer cachexia. Cancer Metab. 2024;12:3. https:\/\/doi.org\/10.1186\/s40170-024-00332-8.","journal-title":"Cancer Metab"},{"key":"4588_CR18","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar S, Duan Q, Wu R, Harris EN, Su Q. Pathophysiological communication between hepatocytes and Non-Parenchyma gender l cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 2021;176:113869. https:\/\/doi.org\/10.1016\/j.addr.2021.113869.","journal-title":"Adv Drug Deliv Rev"},{"key":"4588_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20:633\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00807-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4588_CR20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/HEP.0000000000000386","volume":"78","author":"H Tilg","year":"2023","unstructured":"Tilg H, Adolph TE, Tacke F. Therapeutic modulation of the liver immune microenvironment. Hepatology. 2023;78:1581\u2013601. https:\/\/doi.org\/10.1097\/HEP.0000000000000386.","journal-title":"Hepatology"},{"key":"4588_CR21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver Disease - Novel insights into cellular communication circuits. J Hepatol. 2022;77:1136\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012.","journal-title":"J Hepatol"},{"key":"4588_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","volume":"81","author":"V Taru","year":"2024","unstructured":"Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic Injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81:895\u2013910. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.016.","journal-title":"J Hepatol"},{"key":"4588_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2022.09.005","volume":"78","author":"A Zanetto","year":"2023","unstructured":"Zanetto A, Pelizzaro F, Campello E, Bulato C, Balcar L, Gu W, Gavasso S, Saggiorato G, Zeuzem S, Russo FP, Mandorfer M, Reiberger T, Trebicka J, Burra P, Simioni P, Senzolo M. Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis. J Hepatol. 2023;78:301\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.005.","journal-title":"J Hepatol"},{"key":"4588_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fr\u00fcndt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenh\u00fcner AR, Mertens JC, Rahbari NN, K\u00fctting F, et al. Prognosis of patients with hepatocellular carcinoma treated with Immunotherapy - Development and validation of the CRAFITY score. J Hepatol. 2022;76:353\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.035.","journal-title":"J Hepatol"},{"key":"4588_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","volume":"23","author":"A Colantoni","year":"2024","unstructured":"Colantoni A, Bucci T, Cocomello N, Angelico F, Ettorre E, Pastori D, Lip GYH, Del Ben M, Baratta F. Lipid-Based Insulin-Resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease. Cardiovasc Diabetol. 2024;23:175. https:\/\/doi.org\/10.1186\/s12933-024-02263-6.","journal-title":"Cardiovasc Diabetol"},{"key":"4588_CR26","doi-asserted-by":"publisher","first-page":"108165","DOI":"10.1016\/j.pharmthera.2022.108165","volume":"235","author":"J Zeller","year":"2022","unstructured":"Zeller J, Bogner B, McFadyen JD, Kiefer J, Braig D, Pietersz G, Krippner G, Nero TL, Morton CJ, Shing KSCT, Parker MW, Peter K, Eisenhardt SU. Transitional changes in the structure of C-Reactive protein create highly pro-Inflammatory molecules: therapeutic implications for cardiovascular diseases. Pharmacol Ther. 2022;235:108165. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108165.","journal-title":"Pharmacol Ther"},{"key":"4588_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12876-025-03870-7","volume":"25","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Lin H, Weng X, Dai H, Xu J. Correlation between Hs-CRP-Triglyceride glucose index and NAFLD and liver fibrosis. BMC Gastroenterol. 2025;25:252. https:\/\/doi.org\/10.1186\/s12876-025-03870-7.","journal-title":"BMC Gastroenterol"},{"key":"4588_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.14670\/HH-11-648","volume":"30","author":"R Marcos","year":"2015","unstructured":"Marcos R, Correia-Gomes C, Miranda H, Carneiro F. Liver gender Dimorphism\u2013Insights from quantitative morphology. Histol Histopathol. 2015;30:1431\u20137. https:\/\/doi.org\/10.14670\/HH-11-648.","journal-title":"Histol Histopathol"},{"key":"4588_CR29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jhep.2024.01.036","volume":"80","author":"X-N Wu","year":"2024","unstructured":"Wu X-N, Wang M-Z, Zhang N, Zhang W, Dong J, Ke M-Y, Xiang J-X, Ma F, Xue F, Hou J-J, Ma Z-J, Wang F-M, Liu X-M, Wu R, Pawlik TM, Ye K, Yu J, Zhang X-F, Lyu Y. Sex-Determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology. J Hepatol. 2024;80:928\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.036.","journal-title":"J Hepatol"},{"key":"4588_CR30","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex differences in nonalcoholic fatty liver disease: state of the Art and identification of research gaps. Hepatology. 2019;70:1457\u201369. https:\/\/doi.org\/10.1002\/hep.30626.","journal-title":"Hepatology"},{"key":"4588_CR31","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-Liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700\u201318. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.017.","journal-title":"Cell Metab"},{"key":"4588_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jhep.2020.06.046","volume":"74","author":"K Saboo","year":"2021","unstructured":"Saboo K, Shamsaddini A, Iyer MV, Hu C, Fagan A, Gavis EA, White MB, Fuchs M, Heuman DM, Sikaroodi M, Iyer RK, Gillevet PM, Bajaj JS. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. J Hepatol. 2021;74:80\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.046.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04588-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:04:25Z","timestamp":1781625865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4588"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04588-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CHARLS was approved by the Institutional Review Board of Peking University (approval number: IRB00001052-11015 for the household survey and IRB00001052-11014 for blood samples), and all participants provided written informed consent. All procedures involving human participants were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}